Early-onset disease (at <50 years of age) accounts for 10% of colorectal cancer cases, and the incidence is increasing, particularly in high-income countries. Patients often present with advanced disease in the left colon. One in six patients has deficient DNA mismatch repair. Screening is now recommended to begin at 45 years of age. https://www.nejm.org/doi/full/10.1056/NEJMra2200869
Category: Oncology
Age at Initiation of Lower Gastrointestinal Endoscopy and Colorectal Cancer Risk Among US Women
Importance In the past 4 years, the American Cancer Society and the US Preventive Services Task Force updated recommendations to initiate colorectal cancer (CRC) screening at 45 years of age to address the increasing incidence of CRC among adults younger than 50 years. However, empirical evidence evaluating the potential benefits of screening in younger populations …
A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness
AbstractDespite all the new developments in cancer therapy, the life expectancy of patients with malignant anaplastic brain tumors and glioblastoma multiform (GBM) remains short. Since the establishment of the Di Bella Method (DBM) in cancer therapy, DBM was able to increase the survival rate and life quality, without overt toxicity, in comparison to what is …
Sodium accumulation in breast cancer predicts malignancy and treatment response
BackgroundBreast cancer remains a leading cause of death in women and novel imaging biomarkers are urgently required. Here, we demonstrate the diagnostic and treatment-monitoring potential of non-invasive sodium (23Na) MRI in preclinical models of breast cancer. MethodsFemale Rag2−/− Il2rg−/− and Balb/c mice bearing orthotopic breast tumours (MDA-MB-231, EMT6 and 4T1) underwent MRI as part of …
Continue reading Sodium accumulation in breast cancer predicts malignancy and treatment response
KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer
EP300, a transcription coactivator important in proliferation and differentiation, is frequently mutated in diverse cancer types, including small cell lung cancer (SCLC). While these mutations are thought to result in loss of EP300 function, the impact on tumorigenesis remains largely unknown. Here, we demonstrate that EP300 mutants lacking acetyltransferase domain accelerate tumor development in mouse …
2Medical.News 